2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Molecular Testing, Treatment Considerations, Therapy Sequence, Biological Therapies, Transplantation, Non-Biological Therapies, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Microbiome, Clinical Practice (Health Services and Quality), Clinical Guidelines, Value, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Immunology, GVHD, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Research, AML, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

6039 Oxygenation strategies for acute respiratory failure after allogeneic hematopoietic stem cell transplantation: Results from a prospective multicenter study (CARE-HCT)

Peng Zhao, Zhixue Li2, Sheng-Jin Fan3, Erlie Jiang, MD4, Junbin Hu5, Heng Mei, MD, PhD6, Yi Luo7, Xi Zhang, MD8, Hai-Xia Fu9, Yuanyuan Zhang10, Huiying Zhao11, Fengxue Zhu12, Yu Wang13, Lan-Ping Xu14, Ying-jun Chang15, Xiang-Yu Zhao16, Xiaojun Huang, MD, PhD17, Xiaohui Zhang, MD18
1 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
2 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
3 The First Affiliated Hospital of Harbin Medical University, Harbin, China
4 Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
5 Union Hospital, Tongji Medical College, Wuhan, China
6 Union Hospital, Tongji Medical College, Wuhan, China
7 Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
8 Xinqiao Hospital Army Medical University, Chongqing, China
9 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
10 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
11 Peking University People’s Hospital, Beijing, China
12 Peking University People’s Hospital, Beijing, China
13 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
14 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
15 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
16 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
17 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
18 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China

Introduction

  Acute respiratory failure (ARF) is the leading cause of intensive care unit (ICU) admission among allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Invasive mechanical ventilation (IMV) is a key prognostic predictor of ARF. Optimizing non-invasive oxygenation strategies to avoid IMV is therefore a major treatment goal. Management of post-transplant ARF is further complicated by its diverse etiology, which includes pulmonary lesions and non-pulmonary disorders. Oxygenation strategies for allo-HSCT recipients, however, have not been investigated. Here, we conduct a prospective, multicenter observational study to investigate the prognostic role of oxygenation strategies in adults who developed ARF after allo-HSCT.

Methods

  The Critical Illness Among Recipients of Hematopoietic Cell Transplantation (CARE-HCT) trial is a prospective, multicenter observational study conducted at six medical centers in China (ClinicalTrials.gov identifier, NCT07328724). Participants enrolled in the CARE-HCT trial who fulfilled the following criteria were included for this work: 1) aged older than 18 years at ICU admission; and 2) acute hypoxemic respiratory failure at ICU admission, defined as a PaO2 <60 mmHg or SpO2 <90% on room air, tachypnea >30/min, or respiratory distress or dyspnea at rest. Patients who fulfilled any of the following criteria were excluded: 1) requiring IMV at ICU admission; 2) refusal of IMV or non-invasive ventilation (NIV) by the patient; 3) hypercapnia or isolated cardiogenic pulmonary edema indicating NIV; 4) anatomical factors precluding the use of a nasal cannula; and 5) incomplete outcome or treatment data. The etiology of ARF was determined according to the clinical diagnosis. Confirmed pathogenic evidence was needed for the diagnosis of infection. Non-invasive oxygenation strategy failure was defined as the need for IMV.

Results

  Five hundred seventy-five (575) patients were diagnosed with acute hypoxemic respiratory failure at ICU admission. The median age at ICU admission was 42.5 (IQR, 30.3-54.6) years, and 64.7% of the patients were male. Patients were admitted to ICU at a median duration of 194 (IQR, 90-368) days after transplantation. Infectious causes were confirmed in 40.5% of the patients, and viruses were the most frequently detected pathogens (29.6%). Among patients without confirmed infection, diffuse alveolar hemorrhage (10.4%) and obliterative bronchiolitis (8.3%) were the leading causes of ARF. The median overall survival was 17 (IQR, 5-146) days with an in-ICU mortality of 59.5%. At ICU admission, 102 (17.7%) patients required IMV; NIV was performed for 105 (18.3%) patients and the remaining patients (64.0%) received standard oxygen therapy (including high-flow nasal oxygen). IMV at admission was associated with adverse overall survival (p <0.001), whereas no significant difference was observed between patients receiving NIV and those receiving standard oxygen therapy.

  Non-invasive oxygenation strategy failure occurred in 56 (53.3%) patients receiving NIV and 152 (41.3%) patients receiving standard oxygen therapy. In multivariate logistic analyses adjusted for age, sex, underlying disease, and transplantation type, the oxygenation strategy (NIV versus standard oxygen therapy) was not independently associated with the risk of failure in the total cohort (p =0.095), in the subgroups of patients with (p =0.060) and without (p =0.342) confirmed infections, or in the subgroup of patients with uncontrolled graft-versus-host disease (p =0.876). Nevertheless, patients who failed non-invasive oxygenation strategy had significantly worse overall survival (with versus without, log rank p <0.001), which was comparable to those receiving IMV at ICU admission (p =0.079). Multivariate logistic analysis identified a SpO2/FiO2 ratio <150 mmHg (p <0.001), a respiration rate >30 per minute (p =0.012), confirmed infection (p =0.004), acute kidney injury (p =0.019), vasopressor use (p =0.016), and diffuse alveolar hemorrhage (p <0.001) as independent risk factors for non-invasive oxygenation strategy failure.

Conclusions

  Among patients admitted to ICU with ARF after allo-HSCT, NIV did not reduce the risk of mortality or intubation. Risk factors for non-invasive oxygenation strategy failure were identified.

Peng Zhao: No relevant conflicts of interest to declare.